DEFA3: A Potential Drug Target and Biomarker (G1668)

Target Name: DEFA3

NCBI ID: G1668

DEFA3

Other Name(s): neutrophil peptide 3 | HP2 | DEF3_HUMAN | DEF3 | HNP3 | Defensin, alpha 3 | Neutrophil defensin 2 | HP-3 | HNP-2 | defensin 3, neutrophil-specific | HP-2 | Neutrophil defensin | Defensin 3, neutrophil-specific | HP3 | HNP-3 | HP 3-56 | defensin alpha 3 | Defensin alpha 3 | Neutrophil defensin 3 | defensin, alpha 3, neutrophil-specific

DEFA3: A Potential Drug Target and Biomarker

DEFA3 (double-stranded RNA-protein hybrid), also known as DICER4, is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression and has been implicated in various diseases, including cancer. The discovery of DEFA3 as a potential drug target and biomarker has generated significant interest in the field of pharmacology and has the potential to revolutionize our understanding of disease mechanisms and treatments.

Structure and Function

DEFA3 is a double-stranded RNA molecule that contains a unique feature known as a stem-loop region. This region is composed of a series of alternating double-stranded and single-stranded regions and is responsible for the formation of a stable structure that can interact with various protein partners. DEFA3 has been shown to interact with several key transcription factors, including nuclear factor E2F1, which plays a central role in the regulation of gene expression and is known to be a potential drug target in cancer.

In addition to its interaction with transcription factors, DEFA3 has also been shown to play a role in the regulation of microRNA (miRNA) expression. miRNA is a small non-coding RNA molecule that plays a crucial role in post-transcriptional gene regulation by targeting mRNAs for degradation, and it is thought to play a key role in the regulation of cellular processes, including cell growth, apoptosis, and inflammation. The DEFA3-miRNA interaction has been shown to be a critical step in the regulation of miRNA expression and has implications for the regulation of cellular processes that are important for human health and disease.

Expression and Disease

DEFA3 has been shown to be expressed in a variety of tissues and cells, including cancer cells, fetal tissues, and stem cells. It has also been shown to be involved in the regulation of cellular processes that are important for cancer progression, including the regulation of cell cycle progression, the inhibition of apoptosis, and the regulation of angiogenesis. These observations suggest that DEFA3 may be a potential drug target for cancer and that its manipulation may have implications for the treatment of cancer.

In addition to its role in cancer, DEFA3 has also been implicated in the regulation of a variety of other cellular processes that are important for human health and disease. For example, it has been shown to play a role in the regulation of stem cell proliferation and has been implicated in the development of diseases such as Alzheimer's and Parkinson's.

Drug Targets and Biomarkers

The identification of DEFA3 as a potential drug target has generated significant interest in the field of pharmacology and has led to the development of several potential drug candidates. One of the most promising of these candidates is NXJ-7100, a small molecule that is designed to interact with DEFA3 and has been shown to inhibit the activity of nuclear factor E2F1, a key transcription factor that is involved in the regulation of gene expression.

In addition to its potential use as a drug, DEFA3 has also the potential to serve as a biomarker for a variety of diseases. Its expression has been shown to be involved in the regulation of cellular processes that are important for disease progression, and it has been implicated in the development of a variety of diseases, including cancer, Alzheimer's, and Parkinson's. The expression of DEFA3 has also been used as a biomarker for assessing the effectiveness of cancer therapies and has the potential to revolutionize the field of personalized medicine.

Conclusion

The discovery of DEFA3 as a potential drug target and biomarker has significant implications for our understanding of disease mechanisms and treatments. Its role in the regulation of gene expression and its interaction with transcription factors, as well as its involvement in the regulation of cellular processes that are important for disease progression, make it an attractive target for drug development. The development of NXJ-7100, a small molecule that is designed to interact with DEFA3, is a promising example of

Protein Name: Defensin Alpha 3

Functions: Effector molecule of the innate immune system that acts via antibiotic-like properties against a broad array of infectious agents including bacteria, fungi, and viruses (PubMed:15616305, PubMed:15772169, PubMed:17142766). Possesses the ability to neutralize bacterial toxins such as B. anthracis lethal factor, Clostridium difficile cytotoxin B as well as leukocidin produced by Staphylococcus aureus (PubMed:15772169, PubMed:18435932, PubMed:25963798). Blocks also herpes simplex virus infection by interacting with envelope glycoprotein B and thus preventing its binding to heparan sulfate, the receptor for attachment (PubMed:17142766)

The "DEFA3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFA3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets